Analysis: Pfizer/BioNTech bid for booster doses premature, more data needed -experts

Pfizer Inc's (PFE.N) push for health regulators to authorize a third dose of its COVID-19 shot is not yet backed by evidence, despite the fast-spreading Delta variant, vaccine experts said.

Pfizer and German partner BioNTech SE said last week that they will ask U.S. and European regulators within weeks to authorize a booster dose due to an increased risk of infection after six months.